Endocrine Abstracts

Background: Immune checkpoint inhibitors like monoclonal antibodies targeting programmed death 1 receptor (PD1) or its ligand (PD-L1) have shown antitumor activity in many malignancies by enhancing immune response against cancer cells resulting in significant long-lasting responses. However, this therapy can induce endocrine immune-related adverse events (EirAEs). Thyroid dysfunction is a common EirAE, while adrenal insufficiency (AI) is very uncommon.Ob...

Introduction: Nivolumab is an antibody that binds to and blocks the activation of programmed-death-receptor 1(PD-1), promoting the activation of T-cells against tumor cells. Thyroid dysfunction (TD) is one of the most common immuno-related adverse events, with incidence up to 10% in patients treated with PD-1/PD-L1 blockade.Objective: To report our experience of Nivolumab-TD in patients with advanced cancer.Methods: All patients di...